- Home
- GCT vs ORKA Comparison
GCT vs ORKA Comparison
Compare GCT & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCT
- ORKA
- Stock Information
- Founded
- GCT 2019
- ORKA 2004
- Country
- GCT United States
- ORKA United States
- Employees
- GCT N/A
- ORKA N/A
- Industry
- GCT Catalog/Specialty Distribution
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GCT Consumer Discretionary
- ORKA Health Care
- Exchange
- GCT Nasdaq
- ORKA Nasdaq
- Market Cap
- GCT 685.2M
- ORKA 354.2M
- IPO Year
- GCT 2022
- ORKA N/A
- Fundamental
- Price
- GCT $20.93
- ORKA $12.61
- Analyst Decision
- GCT Buy
- ORKA Strong Buy
- Analyst Count
- GCT 2
- ORKA 8
- Target Price
- GCT $20.50
- ORKA $39.71
- AVG Volume (30 Days)
- GCT 704.1K
- ORKA 331.8K
- Earning Date
- GCT 08-05-2025
- ORKA 08-15-2025
- Dividend Yield
- GCT N/A
- ORKA N/A
- EPS Growth
- GCT 19.58
- ORKA N/A
- EPS
- GCT 3.07
- ORKA N/A
- Revenue
- GCT $1,181,871,000.00
- ORKA N/A
- Revenue This Year
- GCT $1.98
- ORKA N/A
- Revenue Next Year
- GCT $6.50
- ORKA N/A
- P/E Ratio
- GCT $6.81
- ORKA N/A
- Revenue Growth
- GCT 42.89
- ORKA N/A
- 52 Week Low
- GCT $11.17
- ORKA $5.49
- 52 Week High
- GCT $34.28
- ORKA $52.32
- Technical
- Relative Strength Index (RSI)
- GCT 67.78
- ORKA N/A
- Support Level
- GCT $19.23
- ORKA N/A
- Resistance Level
- GCT $20.48
- ORKA N/A
- Average True Range (ATR)
- GCT 0.90
- ORKA 0.00
- MACD
- GCT 0.15
- ORKA 0.00
- Stochastic Oscillator
- GCT 97.82
- ORKA 0.00
About GCT GigaCloud Technology Inc
GigaCloud Technology Inc provides end-to-end and B2B e-commerce solutions for large parcel merchandise. Its B2B e-commerce platform, which is referred to as the GigaCloud Marketplace, integrates everything from discovery, payments, and logistics tools into one easy-to-use platform. It offers online and offline integrated cross-border transaction and delivery services for furniture and large merchandise. Its marketplace seamlessly connects manufacturers in Asia, with resellers in the U.S., Asia, and Europe, to execute cross-border transactions with confidence, speed, and efficiency. It offers a truly comprehensive solution that transports products from the manufacturer's warehouse to end customers, all at one fixed price.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.